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Book Reviews 
Pneutnocystis cavinii pneumonia 
P. D. WALZER 
London: Marcel Dekker, 1993, 744 pages 
Given that it is confined to discussion of Pneumo- 
cystis carinii pneumonia, one is immediately 
impressed by the size of this text for which 42 
predominantly U.S.A.-based authors have written 31 
chapters filling well over 600 pages. Initial chapters 
cover in detail the morphology, biochemistry, in vitro 
cultivation and genetic aspects of P. carinii. Subse- 
quent chapters discuss clinical, pathological, and 
radiological features as well as treatment. On the 
basis of its scope, detailed discussion and a large 
number of references, generally between 50 and 100 
for each chapter, the book fulfils its aim to be a 
reference text but is let down by a disappointingly 
scant subject index and absence of histological figures 
in colour. 
There is, inevitably for a multiple-author book, 
disagreement between chapters. For instance, 
whereas it is stated in one chapter that P. carinii 
pneumonia results from reactivation in immunocom- 
promised individuals following primary infection 
early in life, another chapter provides convincing 
evidence that pneumonia results from reinfection, on 
the basis that the most sensitive techniques do not 
detect the organism at post mortem of immunocom- 
petent subjects. In favour of this text and of particu- 
lar relevance to respiratory physicians, is the in-depth 
and extensively referenced discussion of methods of 
diagnosis, and treatment options. On this basis, the 
book might be regarded as essential for clinicians 
specializing in HIV infection, and a useful library 
reference for respiratory physicians with an interest. 
S. Lozewicz 
Clinical development of drugs against asthma 
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This issue reports the outcome of the deliberations 
by the expert panel on Clinical Development of 
Drugs Against Asthma. Their objective was to 
present proposals for the efficient clinical develop- 
ment of drugs to treat asthma, concentrating on the 
clinical rather than non-clinical studies. The report is 
arranged in sections, beginning with pre-clinical 
pharmacology, continuing with the clinical trial 
design for bronchodilator drugs and disease- 
modifying drugs, and ending with sections on special 
patient groups, statistics, compliance and ethical con- 
siderations. An appendix contains a specimen clinical 
trial protocol. 
The report is well written and comprehensive, with 
relevant references at the end of each section, for 
further reading. The sections on inhaled drug delivery 
and efficacy (section 5) and equivalence of anti- 
asthma preparations (section 6) are particularly well 
written. The report provides information that will be 
useful to the newcomer and to those already involved 
in the design and carrying-out of clinical trials in 
asthma. There is some repetition, particularly in the 
sections on the safety and efficacy of bronchodilator 
drugs (section 7) and disease-modifying drugs (sec- 
tion 8), which could have been accommodated in 
one section. Each section concludes with rec- 
ommendations for future conduct of that aspect of 
research, but these are brief and in some sections, too 
general. Considering the remit of the panel, more 
comprehensive recommendations would have been 
appropriate. 
The report does have some limitations, particularly 
for those actively involved in setting up and running 
clinical trials. The general nature of the sections on 
trial design fail to address some specific concerns in 
sufficient detail. For example, trial design (parallel 
group, cross-over design) are discussed briefly but 
considering the importance of design and choice of 
the type best suited to answering different hypoth- 
eses, expansion of this section would have been 
helpful. The same is true for the inclusion of inhaled 
steroid withdrawal to create symptomatic asthma in 
trial design, an issue much debated. The section on 
special patient groups, such as the use of women of 
child-bearing potential, always a limiting factor 
in recruitment, could have been expanded and 
recommendations for their place in trials given. 
Despite these minor criticisms, the report does 
cover its stated aims and should be recommended 
reading for anyone undertaking research into anti- 
asthma drugs. 
L. Kuitert 
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